ESR1-Mutated, ER-Positive, HER2-Negative Metastatic Breast Cancer
ATHAAthira PharmaCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Lasofoxifene (Estrogen Receptor Modulator) in ESR1-Mutated, ER-Positive, HER2-Negative Metastatic Breast Cancer. The expected timing is based on the latest available company guidance and may change.
05/07/26:- ELAINE-3 enrollment expected Q4 2026; topline data expected H2 2027. 08/12/26:- ELAINE-3 presented at Dava Oncology Summit Aug 19-20, 2026. 08/14/26:- ELAINE-3 enrolled 495 patients; enrollment will complete Q4 2026. Topline data will be available H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.